Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

e for sale in Europe and Australia through distributorship agreements.

Additionally, InnerCool is developing a new class of targeted organ-specific cooling applications, including the UroCool(TM) Targeted Tissue Cooling System, a pelvic cooling catheter system designed to induce localized cooling during surgery for prostate cancer. Researchers at the University of California, Irvine believe that therapeutic cooling during prostate surgery (which includes both traditional open surgical approaches and newer robotic-assisted techniques) can reduce tissue damage and inflammation and thereby provide a faster return of bladder control (continence) and possibly erectile function (potency). The specialized UroCool pelvic cooling catheter is being integrated with InnerCool's current Celsius Control Console which has been marketed and sold since 2003 and a regulatory application for FDA 510(k) clearance of the UroCool(TM) catheter is expected to be submitted in the first quarter of 2009.

InnerCool continues its sponsorship of a pilot study to evaluate the use of early and rapid cooling in heart attack patients, which is being co-sponsored and conducted by the interventional cardiology center at Lund University Hospital, Sweden. The ongoing clinical study, called RAPID MI-ICE (Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention), is expected to enroll approximately 20 patients who present within six hours of their heart attack and require angioplasty and stent procedures in order to restore blood flow to the heart. Preclinical and preliminary clinical data suggest that rapid patient cooling using intravenous cold saline in combination with endovascular hypothermia can be initiated without causing delay of reperfusion therapy and may have the potential to enable interventional cardiologists to dramatically reduce heart tissue damage following a heart attack. The Company expects to announce results of the RAPID M
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...alif., Nov. 6 Intarcia Therapeutic...TCA 650 (DUROS® continuous delivery of exenat...at the Ninth Annual Diabetes Technology Meeting in...om.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, ... ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces...
(Date:11/5/2009)..., N.J., Nov. 5 DSM Pharmaceutical ...cturing alliance with Galenix, Saint Jean D,Illac,...l scale manufacturing partner for Galenix commerci...ix will collaborate on business development opport...ogies, based on the strength of Galenix in drug pr...
(Date:11/5/2009)...N.Y., Nov. 5 BioSpecific...ceutical company developing first-in-class collage... results for the third quarter ended September 30,...ptember of this year, the FDA,s Arthritis Advisory...2-0, the approval of XIAFLEX(TM) for the treatment...
(Date:11/5/2009)...xas, Nov. 5 SpineSmith Partners ha...to co-develop a unique scaffold that mimics the st...luation of several commercial products by SpineSmi...any believes the GenOsteo scaffold represents a si... unique and ideal environment for the delivery of ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
...lopers will have the chance to combine their ideas...st annual Games+Learning+Society conference at t...being held by Games And Professional Practice Simu...Distributed Learning (ADL) Co-Lab and a group of i...Speakers include educators and developers from com...
...terman, here are the top 10 reasons to be at the B...hiladelphia. , , 10. You can pick up some great to...he coin of the realm in the BIO exhibit floor, whe...e set up shop. Mini-soccer balls, mini-Capitol dom... Crowd at BIO 9. You can go on a diet. Believe ...
... of GE Healthcare Technologies in Waukesha, will b...on next year as part of the parent company,s effor...n will succeed Bill Castell as head of GE Healthca... of the Waukesha-based GE Healthcare Technologies ... after Immelts promotion to succeed Jack Welch as ...
Other Biology Technology:Education conference to draw together games researchers 2From the BIO floor 2From the BIO floor 3
(Date:11/5/2009)...tate University has been awarded a training grant ...e Foundation under its Integrative Graduation Educ...is the first IGERT grant to be awarded to Kent Sta...Recovery and Reinvestment Act of 2009, runs throug...focuses on environment aquatic resource sensing (E...
(Date:11/4/2009)...ver, BC - Lowly bacteria, it turns out, hold the p...g plants around the world clean up toxic waste on ...cifically RDX, were invented back in World War II ...es. These high-energy compounds are often used to...ersion of TNT. , But with increased knowledge ...
(Date:11/4/2009)...DWOOD CITY, Calif., Oct. 20 Digita...nd authentication solutions, today announced that ...ale (POS) software for quick-service restaurants, ...r NextGen POS and Classic POS solutions. WAND,s qu...etrics to boost cashier accountability and deter u...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Genomic research will enable greener cleanup of military explosive test sites 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 1Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 2Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 3Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 4Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 5Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 6Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 1Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 2Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 3Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 4Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 5
...ifying Bacillus anthracis, the causative agent of ...e U.S. Food and Drug Administration (FDA). The tes... scientists at the U.S. Army Medical Research Inst... its performance and reliability when used with cl...hage Assay was first developed by the Centers for ...
...r Mark Pagani in the Department of Geology and Geo...t detailed history of atmospheric carbon dioxide b...sotopes of carbon in a National Science Foundation... energy we consume, each of us makes a contributio...dioxide and methane, in the Earth,s atmosphere," s...
...ly notice if the outside world suddenly went dark ...ur blinks, even though they cause a similar reduct...y are we not aware of the frequent mini-blackouts ...vered that visual sensitivity begins decreasing im... underlying this process have until now remained u...
Other Biology News:Anthrax test, developed by army and CDC, receives FDA approval 2Anthrax test, developed by army and CDC, receives FDA approval 3Invasive parasite destroying fish species 2Blink, and the brain misses it 2
Biomek FX Laboratory Workstation (High Throughput) from Beckman Coulter
Methlation Analysis/Bisulfite Sequencing from Seqwright
...ncourt offers quick turnaround sequencing of indiv...ow copy and high copy plasmids. Agencourt's world-...ses over 20 million Phred20 bases per day. The ke...e Sequencing service are 24 48 hour sample turnar...
Acridinium Labeling Buffer from Cayman Chemical
Biology Products: